HRP20181353T1 - Tuberkulozni protein rv2386c, njegovi pripravci i upotreba - Google Patents

Tuberkulozni protein rv2386c, njegovi pripravci i upotreba

Info

Publication number
HRP20181353T1
HRP20181353T1 HRP20181353TT HRP20181353T HRP20181353T1 HR P20181353 T1 HRP20181353 T1 HR P20181353T1 HR P20181353T T HRP20181353T T HR P20181353TT HR P20181353 T HRP20181353 T HR P20181353T HR P20181353 T1 HRP20181353 T1 HR P20181353T1
Authority
HR
Croatia
Prior art keywords
tuberculosis
compositions
rv2386c protein
rv2386c
protein
Prior art date
Application number
HRP20181353TT
Other languages
English (en)
Inventor
James Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals S.A.
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A., Glaxo Group Limited filed Critical Glaxosmithkline Biologicals S.A.
Publication of HRP20181353T1 publication Critical patent/HRP20181353T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
HRP20181353TT 2008-07-25 2018-08-23 Tuberkulozni protein rv2386c, njegovi pripravci i upotreba HRP20181353T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8369908P 2008-07-25 2008-07-25
EP09781057.6A EP2315834B1 (en) 2008-07-25 2009-07-24 The tuberculosis rv2386c protein, compositions and uses thereof
PCT/EP2009/059585 WO2010010179A1 (en) 2008-07-25 2009-07-24 The tuberculosis rv2386c protein, compositions and uses thereof

Publications (1)

Publication Number Publication Date
HRP20181353T1 true HRP20181353T1 (hr) 2018-10-19

Family

ID=41227131

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181353TT HRP20181353T1 (hr) 2008-07-25 2018-08-23 Tuberkulozni protein rv2386c, njegovi pripravci i upotreba

Country Status (23)

Country Link
US (4) US20110206712A1 (hr)
EP (1) EP2315834B1 (hr)
JP (2) JP5981138B2 (hr)
KR (1) KR20110049834A (hr)
CN (2) CN106866801A (hr)
AU (1) AU2009273132B2 (hr)
BR (1) BRPI0916704A2 (hr)
CA (1) CA2731547C (hr)
CO (1) CO6351811A2 (hr)
CY (1) CY1121632T1 (hr)
DK (1) DK2315834T3 (hr)
EA (1) EA201100070A1 (hr)
ES (1) ES2685498T3 (hr)
HR (1) HRP20181353T1 (hr)
HU (1) HUE039159T2 (hr)
IL (1) IL210589A (hr)
LT (1) LT2315834T (hr)
MX (1) MX2011000982A (hr)
PL (1) PL2315834T3 (hr)
PT (1) PT2315834T (hr)
SI (1) SI2315834T1 (hr)
UA (1) UA107329C2 (hr)
WO (1) WO2010010179A1 (hr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1994409A2 (en) * 2006-03-14 2008-11-26 Oregon Health and Science University Methods for producing an immune response to tuberculosis
WO2009158284A2 (en) * 2008-06-26 2009-12-30 Mayo Foundation For Medical Education And Research Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
CA2731549C (en) * 2008-07-25 2018-07-17 Glaxo Group Limited Compositions and methods for treating tuberculosis
PT2315834T (pt) * 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa A proteína rv2386c de tuberculose, composições e as suas utilizações
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
CN107478849B (zh) * 2013-05-31 2019-08-20 中国医学科学院病原生物学研究所 用于结核病诊断和预防的蛋白
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
ES2897933T3 (es) 2014-08-15 2022-03-03 Oxford Immunotec Ltd Proteínas de Mycobacterium tuberculosis
CN105572352B (zh) * 2016-02-17 2017-07-28 遵义医学院附属医院 一组结核潜伏感染诊断标志物及其用途
EP3551222A1 (en) 2016-12-07 2019-10-16 GlaxoSmithKline Biologicals SA Novel process
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
CN109234414B (zh) * 2018-06-29 2022-05-17 周琳 结核分枝杆菌的对氨基水杨酸耐药性诊断标志物及其应用
CN108866213A (zh) * 2018-06-29 2018-11-23 周琳 结核分枝杆菌利福平耐药性诊断标志物及其应用
CN108950031A (zh) * 2018-06-29 2018-12-07 周琳 结核分枝杆菌的利福平耐药性诊断标志物及其应用
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
BR112021025172A2 (pt) * 2019-06-14 2022-01-25 Statens Seruminstitut Proteínas de fusão para vacinas de tuberculose
CN112457410B (zh) * 2020-11-05 2023-04-07 迈克生物股份有限公司 用于结核分枝杆菌感染检测的抗原组合物
DE202022102137U1 (de) 2022-04-21 2022-04-28 Damayanthi Dalu Eine neue Zusammensetzung zur Behandlung von Tuberkulose
CN115725607B (zh) * 2022-07-14 2023-11-28 山东第一医科大学附属省立医院(山东省立医院) 一种鼻疽诺卡菌的致病靶基因及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49909A1 (en) 1992-06-25 1998-06-15 Smithkline Beecham Biolog Vaccine composition containing adjuvants
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
CA2326598C (en) 1998-04-07 2014-06-10 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
ATE442866T1 (de) 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20030236393A1 (en) 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
WO2005076010A2 (en) 2004-02-06 2005-08-18 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
CN101273055B (zh) * 2005-04-29 2016-03-16 葛兰素史密丝克莱恩生物有限公司 用于预防或治疗结核分枝杆菌感染的新方法
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
LT2137210T (lt) 2007-03-02 2016-12-27 Glaxosmithkline Biologicals Sa Naujas būdas ir kompozicijos
CA2731549C (en) 2008-07-25 2018-07-17 Glaxo Group Limited Compositions and methods for treating tuberculosis
PT2315834T (pt) 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa A proteína rv2386c de tuberculose, composições e as suas utilizações
PT2315773T (pt) 2008-07-25 2016-11-23 Glaxosmithkline Biologicals Sa Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
CN104107425B (zh) 2009-04-24 2018-07-17 国家血清研究所 预防再激活的结核病tb疫苗
WO2010132112A2 (en) 2009-05-14 2010-11-18 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
WO2011092253A1 (en) 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens

Also Published As

Publication number Publication date
CY1121632T1 (el) 2020-07-31
US20140314802A1 (en) 2014-10-23
SI2315834T1 (sl) 2018-09-28
CA2731547C (en) 2019-04-30
HUE039159T2 (hu) 2018-12-28
US20110206712A1 (en) 2011-08-25
JP6104326B2 (ja) 2017-03-29
JP2016000734A (ja) 2016-01-07
CN102165064A (zh) 2011-08-24
EA201100070A1 (ru) 2011-10-31
US20170065697A1 (en) 2017-03-09
KR20110049834A (ko) 2011-05-12
CO6351811A2 (es) 2011-12-20
WO2010010179A1 (en) 2010-01-28
BRPI0916704A2 (pt) 2020-08-18
IL210589A (en) 2015-05-31
EP2315834A1 (en) 2011-05-04
MX2011000982A (es) 2011-03-02
IL210589A0 (en) 2011-03-31
AU2009273132B2 (en) 2015-09-03
US10286053B2 (en) 2019-05-14
AU2009273132A1 (en) 2010-01-28
ES2685498T3 (es) 2018-10-09
PL2315834T3 (pl) 2018-12-31
UA107329C2 (uk) 2014-12-25
LT2315834T (lt) 2018-09-10
JP2011528896A (ja) 2011-12-01
US20140086948A1 (en) 2014-03-27
CN102165064B (zh) 2017-06-20
JP5981138B2 (ja) 2016-08-31
DK2315834T3 (en) 2018-08-20
PT2315834T (pt) 2018-08-10
CN106866801A (zh) 2017-06-20
US9480735B2 (en) 2016-11-01
CA2731547A1 (en) 2010-01-28
EP2315834B1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
HRP20181353T1 (hr) Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
IL250938A0 (en) Enzymatic fusion proteins, preparations containing them and their uses
HK1211040A1 (en) New albumin binding compositions, methods and uses
IL211762A0 (en) Pegylated opiods, compositions comprising the same and uses thereof
IL212836A0 (en) Azaquinolinone derivatives, compositions comprising the same and uses thereof
IL230759A0 (en) Converted acyl anilide, the pharmaceutical composition containing it and its uses
IL220283A0 (en) 4-oxo-ih-quinoline-3- carboxamides, compositions comprising the same and uses thereof
EP2153838A4 (en) ANTI-NOROVIRUS AGENT AND COMPOSITION COMPRISING SAME
PL2271725T3 (pl) Kompozycje zawierające 2,3,3,3-tetrafluoropropen i 1,1,1-trifluoropropen
IL212278A0 (en) Morpholinopurine derivatives, compositions comprising the same and uses thereof
ZA201103584B (en) Whey protein compositions,methods and uses
IL211284A0 (en) Antibodies binding ccr2, compositions comprising the same and uses thereof
IL210722A0 (en) Benzazepine derivatives, compositions comprising the same and uses thereof
IL205705A0 (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
IL213613A0 (en) Pyrazine derivatives, compositions comprising the same and uses thereof
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
GB0601143D0 (en) Uses, methods and compositions
ZA201005278B (en) Folates, compositions and uses thereof
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
IL207372A0 (en) Phenylpyrrole derivatives, compositions comprising the same and uses thereof
GB0706077D0 (en) Methods, Compositions and uses thereof
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
IL213043A0 (en) Lantibiotic carboxyamide derivatives, compositions comprising the same and uses thereof
IL236601A0 (en) Antibodies against cytomegalovirus, preparations containing them and their uses
IL207639A0 (en) Pyrrolopyrimidinecarboxamide compounds, compositions comprising the same and uses thereof